Next 10 |
home / stock / xomao / xomao news
2024-07-02 09:00:25 ET XOMA Corp (XOMAO) declaring a stock dividend of $0.52344 per share on Ex-Date : July 03, 2024. Shareholders on record as of July 03, 2024 are eligible for the dividend. The payment date is scheduled for July 15, 2024, and the declaration was officially made on...
2024-06-29 02:31:45 ET Summary XOMA Corporation operates as a biotechnology royalty aggregator, acquiring economic rights to milestones and royalties from approved or clinical-stage drugs. XOMA’s diverse IP portfolio spans various therapeutic areas, including oncology, immu...
EMERYVILLE, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has received an $8.1 million milestone payment from Viracta Therapeutics, Inc., related to Day One Biopharmaceuticals’ recent sale of its Priority Revie...
2024-06-04 04:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-25 06:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members of its Executive Team will participate in the H.C. Wainwright 2 nd Annual Bioconnect Investor Conference at NASDAQ being held on May 20, 2024, in ...
Earned $9 million milestone upon U.S. Food and Drug Administration’s approval of Day One’s OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired Kinnate Pharmaceuticals, adding at least $9.5 million in...
Organon, a global women’s healthcare company, initiated XACIATO™ commercial activities in the fourth quarter of 2023 XOMA further expands its late-stage portfolio with synthetic royalty and milestone interests in two additional women’s health assets: Ovaprene ...
2024-04-25 18:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
XOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation EMERYVILLE, Calif., April 25, 2024 (GLOBE N...
News, Short Squeeze, Breakout and More Instantly...
XOMA Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock Company Name:
XOMAO Stock Symbol:
NASDAQ Market:
XOMA Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock Website:
2024-07-02 09:00:25 ET XOMA Corp (XOMAO) declaring a stock dividend of $0.52344 per share on Ex-Date : July 03, 2024. Shareholders on record as of July 03, 2024 are eligible for the dividend. The payment date is scheduled for July 15, 2024, and the declaration was officially made on...
EMERYVILLE, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has received an $8.1 million milestone payment from Viracta Therapeutics, Inc., related to Day One Biopharmaceuticals’ recent sale of its Priority Revie...
2024-06-04 04:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...